Herceptin® is a monoclonal antibody: a man-made copy of proteins that bind, in this case, to cells' HER2 receptors, helping to block them from transmitting growth signals to cancerous cells.

This image accompanied the report "Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site," by J. Bostrom et. al. appearing in the March 20, 2009 issue of ...

The research, which comes from several groups including Genentech, makers of the prevailing anti-HER2 treatment ... By the late ’90s, a drug called Herceptin that targeted the HER2 receptor, sped into ...

But the situation is different with cancer drugs. Herceptin, for example, is given at doses of 500 mg or more. “A concentrated antibody formulation like 100 mg/ml would take at least 5 ml to ...

Herceptin is a humanized monoclonal antibody (MAb) targeted against Her-2/neu, a cell surface receptor protein that is abnormally abundant in 25 to 30 percent of breast cancers. MAbs were the darlings ...

If you have HER2-positive breast cancer, your options for treatment will depend on several factors, such as the stage of cancer (early or metastatic) and the hormone receptor status of the tumor.

MacroGenics argues that margetuximab works by tweaking the “Fc” part of Herceptin ... antibody – so that it interacts more efficiently with the immune system and produces a stronger anti ...

The FDA expanded the approval of trastuzumab deruxtecan for treatment of breast cancer.The new indication applies to use of ...

Phesgo comes in a single-dose vial and can be dosed as a subcutaneous injection, while at the moment breast cancer patients the two anti-HER2 drugs separately receive Herceptin as a subcutaneous ...